Hormonal therapy in cancer of the breast. II. Effect of methylandrostenediol on clinical course and hormonal excretion

✍ Scribed by Albert Segaloff; Douglas Gordon; Benjamin N. Horwitt; Joseph V. Schlosser; Paul J. Murison

• Publisher: John Wiley and Sons
• Year: 1952
• Tongue: English
• Weight: 312 KB
• Volume: 5
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(195203)5:2<271::aid-cncr2820050212>3.0.co;2-w

✦ Synopsis

HE RESULTS of a recent study on patients T with advanced carcinoma of the breast receiving testosterone propionate showed an apparent correlation between creatinuria and clinical course.5 In general, patients who improved with therapy exhibited a decrease in creatinuria whereas those who failed to improve showed an increase. Indeed, it has been our observation that with progression of the disease there is a pronounced increase in creatinuria. For this reason, it was decided to treat these patients with a steroid that would be expected to have an effect on creatine metabolism and that also preferably lacked the degree of androgenicity of testosterone. Since methylandrostenediol fulfilled these requirements and in addition was available in sufficient quantity, it was selected for clinical trial in Datients with advanced cancer of the breast.

MATERIAL AND METHODS

Since there is at present no generally cepted method for steroid nomenclature, compound employed has been designated acthe according to the nomenclature proposed by Fieser and Fieser as 1 7a-methyl-h5-androstene-3p, Updiol. This compound has a melting point of 204" C. It was designated as compound no.